Sourasky Medical Center (Ichilov)
| Israel | Turquia | Áustria | |
| Aférese terapêutica | - | de $1,350 | - |
| Plasmaférese | de $2,200 | de $1,200 | de $2,000 |
| Troca de plasma | - | de $3,900 | - |
| Plasmaférese DFPP | - | de $1,850 | - |
| Aférese seletiva | - | de $1,550 | - |
A Bookimed não adiciona taxas extras aos preços de Aférese terapêutica. As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais em Aférese terapêutica e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de Aférese terapêutica.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Pazit Beckerman is a nephrologist with over 24 years of clinical practice in Israel. She specializes in chronic kidney disease (CKD), acute kidney injury (AKI), hemodialysis and peritoneal dialysis, hypertension-related kidney disease, glomerular diseases and proteinuria, electrolyte disorders, and kidney involvement in systemic diseases.
She served as Acting Director in 2020, Deputy Director from 2018 to 2020, and Senior Physician in the Department of Nephrology at Sheba Medical Center. She also heads the Israeli Dialysis Registry.
Education and training: MD, Hebrew University–Hadassah. Nephrology residency, Hadassah. Fellowship in nephrology, Sheba Medical Center. Biomedical Computational Studies, Bar-Ilan University. Postdoctoral fellowship, University of Pennsylvania.
Her research focuses on AKI, immune-related kidney complications, and chronic kidney disease. She has authored many publications. She is a member of the American Society of Nephrology and a board member of the Israeli Society of Nephrology and Hypertension.
Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.
He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.
He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.